Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SBX-2023
- Development stage
- Preclinical
- Lead developer
- Stramsen Biotech
01
Overview
**SBX-2023** is a plant-based therapeutic candidate being developed by Stramsen Biotech for peripheral neuropathic disorders. The company identifies it as one of its plant-derived pharmaceutical pipeline assets, but has not publicly disclosed its molecular composition, biological target, mechanism of action, dosage form, route of administration, or clinical phase for this specific candidate.
Beyond the preview
Go deeper on SBX-2023.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SBX-2023.